MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis

Site Image

Study Overview

This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with generalized Myasthenia Gravis.

All participants will be consented and enrolled by the Penn PI or Sub-I. Referrals will be accepted but we plan to recruit patients from within Penn Medicine clinics. 

  • Study Identifier: 833604

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email